ArticlePloS one2021
Clinical and economic impact of universal varicella vaccination in Norway: A modeling study.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Pooled it
- Safety, immunogenicity, and effectiveness of the MAV/06 varicella vaccine: A comprehensive review of a new strain vaccine.Human vaccines & immunotherapeutics · 2026Review
- Health Economic Evaluation of Varicella Vaccination Within the Swedish National Vaccination Programme for Children.Acta paediatrica (Oslo, Norway : 1992) · 2026Article
- Estimating the Long-Term Clinical and Economic Impact of Universal Varicella Vaccination in Portugal Using a Dynamic Transmission Model.PharmacoEconomics - open · 2026Article
- Article
- Impact of natural and socio-economic factors on varicella incidence in children in Shanghai, 2013-2022.Frontiers in public health · 2025Article
- The clinical and economic costs associated with regional disparities in varicella vaccine coverage in Italy over 50 years (2020-2070).Scientific reports · 2024Article
- Universal varicella vaccination in Denmark: Modeling public health impact, age-shift, and cost-effectiveness.PLOS global public health · 2023Article
- Assessing vaccine effectiveness for varicella in Wuxi, China: a time-series analysis.Annals of medicine · 2023Article
- The health and economic impact of switching vaccines in universal varicella vaccination programs using a dynamic transmission model: An Israel case study.Human vaccines & immunotherapeutics · 2022Article
- Association of asthma and herpes zoster, the role of vaccination: A literature review.Immunity, inflammation and disease · 2022Review
- Article
- Reconstructing the transmission dynamics of varicella in Japan: an elevation of age at infection.PeerJ · 2022Article
- The Long-Term Clinical and Economic Impact of Universal Varicella Vaccination in Slovenia.Journal of health economics and outcomes research · 2022Article
- Assessing the use of antibiotics and the burden of varicella in Belgium using a retrospective GP database analysis.BMC infectious diseases · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNorway has not implemented universal varicella vaccination, despite the considerable clinical and economic burden of varicella disease.
methodsAn existing dynamic transmission model of varicella infection was calibrated to age-specific seroprevalence rates in Norway. Six two-dose vaccination strategies were considered, consisting of combinations of two formulations each of a monovalent varicella vaccine (Varivax® or Varilrix®) and a quadrivalent vaccine against measles-mumps-rubella-varicella (ProQuad® or PriorixTetra®), with the first dose given with a monovalent vaccine at age 15 months, and the second dose with either a monovalent or quadrivalent vaccine at either 18 months, 7 or 11 years. Costs were considered from the perspectives of both the health care system and society. Quality-adjusted life-years saved and incremental cost-effectiveness ratios relative to no vaccination were calculated. A one-way sensitivity analysis was conducted to assess the impact of vaccine efficacy, price, the costs of a lost workday and of inpatient and outpatient care, vaccination coverage, and discount rate.
resultsIn the absence of varicella vaccination, the annual incidence of natural varicella is estimated to be 1,359 per 100,000 population, and the cumulative numbers of varicella outpatient cases, hospitalizations, and deaths over 50 years are projected to be 1.81 million, 10,161, and 61, respectively. Universal varicella vaccination is projected to reduce the natural varicella incidence rate to 48-59 per 100,000 population, depending on the vaccination strategy, and to reduce varicella outpatient cases, hospitalizations, and deaths by 75-85%, 67-79%, and 75-79%, respectively. All strategies were cost-saving, with the most cost-saving as two doses of Varivax® at 15 months and 7 years (payer perspective) and two doses of Varivax® at 15 months and 18 months (societal perspective).
conclusionsAll modeled two-dose varicella vaccination strategies are projected to lead to substantial reductions in varicella disease and to be cost saving compared to no vaccination in Norway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.